Premium
Polymer Blend Particles with Defined Compositions for Targeting Antigen to Both Class I and II Antigen Presentation Pathways
Author(s) -
Tran Kenny K.,
Zhan Xi,
Shen Hong
Publication year - 2014
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201300306
Subject(s) - antigen , methacrylate , antigen presentation , materials science , immune system , cd8 , antibody , polymer , chemistry , immunology , t cell , medicine , copolymer , composite material
Defense against many persistent and difficult‐to‐treat diseases requires a combination of humoral, CD4 + , and CD8 + T‐cell responses, which necessitates targeting antigens to both class I and II antigen presentation pathways. In this study, polymer blend particles are developed by mixing two functionally unique polymers, poly(lactide‐ co ‐glycolide) (PLGA) and a pH‐responsive polymer, poly(dimethylaminoethyl methacrylate‐ co ‐propylacrylic acid‐ co ‐butyl methacrylate) (DMAEMA‐ co ‐PAA‐ co ‐BMA). Polymer blend particles are shown to enable the delivery of antigens into both class I and II antigen presentation pathways in vitro. Increasing the ratio of the pH‐responsive polymer in blend particles increases the degree of class I antigen presentation, while maintaining high levels of class II antigen presentation. In a mouse model, it is demonstrated that a significantly higher and sustained level of CD4 + and CD8 + T‐cell responses, and comparable antibody responses, are elicited with polymer blend particles than PLGA particles and a conventional vaccine, Alum. The polymer blend particles offer a potential vaccine delivery platform to generate a combination of humoral and cell‐mediated immune responses that insure robust and long‐lasting immunity against many infectious diseases and cancers.